RTI-HS gastroenterologist Allen Mangel will present data from a 596 subject Phase 2b study of asimadoline, a drug candidate for the treatment of irritable bowel syndrome (IBS). The talk will be featured in a late-breaking oral presentation session Tuesday, May 20th at the Digestive Disease Week 2008 (DDW 2008) Annual Meeting in San Diego. Lynne Hamm and Jeff Buda, also RTI-HS employees, are co-authors on the presentation as well, as are staff from Tioga Pharmaceutics.
Asimadoline is an orally administered small molecule that is a highly selective kappa opioid receptor agonist. Kappa opioid receptors are found in the digestive tract and are believed to play an important role in control of visceral pain and bowel motility. Asimadoline was originally discovered by Merck KGaA of Darmstadt, Germany. In 2005, Tioga purchased asimadoline from Merck and acquired by assignment all worldwide rights. Asimadoline has been tested in over 1100 subjects and has demonstrated a promising safety profile. Tioga contracted RTI-HS to manage the clinical trials.
To learn more about DDW 2008, please click here. If you plan to attend the conference and would like to arrange a meeting with Dr. Mangel, please
email him directly.